Sep. 11 at 3:30 PM
$CRDL — preliminary US
$150M base shelf prospectus filed in Canada + Form F-10 with the SEC, giving flexibility to raise via shares, debt, warrants, or units over 25 months. No current offering, no obligation to sell.
Filing coincides with Phase 3 MAVERIC (recurrent pericarditis) nearing target enrollment, plus positive Phase 2 ARCHER data (acute myocarditis) and CRD-38 advancing toward first-in-human testing. Also includes expanded R&D/expense disclosure requested by Ontario Securities Commission, no changes to prior financials. Future draw could mean dilution, watch enrollment completion and cash runway.
$CRDL #Biotech #Cardiology
https://prismmarketview.com/cardiol-therapeutics-files-us150-million-shelf-prospectus-ahead-of-cardiolrx-milestones/
